HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry ...

the first HIV fusion inhibitor. [1] Coreceptor CCR5 antagonists, which provide a novel mechanism of action, are a recent addition to the armamentarium of antiretroviral agents. Maraviroc ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Among the CCR5 inhibitors developed so far, maraviroc is the first drug that has been approved by the US FDA for treating patients with R5 HIV-1. Although many CXCR4 inhibitors, some of which are ...

Individuals carrying this variant exhibited lower CCR5 expression and lower rates of HIV-1 infection in their cells. Before initiating ART, VNPs showed significantly lower total and intact HIV-1 ...

Dr He used CRISPR or Cas9, which stands for CRISPR-associated protein 9, to target a gene called CCR5, which codes for a protein used by the human immunodeficiency virus-1 (HIV-1) to enter cells.

The most common strain, called HIV-1 group M, accounts for around 95 per ... HIV infects cells by attaching to a protein on their surface, called CCR5. Some people have a genetic mutation that ...